Abstract: Provided are various embodiments relating to compositions and methods for treating vascular disease, including core NOX1 promoters and variants thereof for regulating expression of transgenes in response to vascular pathology and allowing for increased transgene loading capacity. Also provided are variant FOXP polypeptides having a zinc finger and leucine zipper region of a different FOXP polypeptide. Further provided are vectors comprising the core NOX1 promoters and/or a coding sequence for variant FOXP polypeptides described herein and optionally coding sequence(s) for one or more additional therapeutic polypeptide(s), such as IL10, for treating inflammation-associated diseases, such as vascular disease. Also provided is a screening model for testing therapeutic agents capable of treating established and ongoing atherosclerotic pathology.

Abstract: The present disclosure relates to compositions, methods of preparation of the compositions, and methods including administration of said compositions for the prevention of neurological damage associated with cerebral ischemia.

Abstract: Disclosed are methods, systems, and computer program products for using liquid chromatography/tandem mass spectrometry (LC-MS/MS) for the analysis of endogenous biomarkers, such as PGD2, in a biological sample. More specifically, the methods, systems, and computer program products are described for detecting and quantifying the amount of an PGD2 in a sample. The quantitative analysis may be helpful in making clinical diagnoses.

Abstract: Oral composition and a method for the treatment of coronaviruses infections in humans and animals. The method includes the steps of administering orally a methionine cleaving-enzyme; administering orally or parentally a protease inhibitor; and orally administering pyridoxal-L-phosphate in a fluid.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: In a method for an actuation of a magnetic resonance device for capturing image data from an examination region of an examination object, at least one first control sequence is provisioned, the magnetic resonance device is actuated according to the at least one first control sequence to capture first data from the examination object, the first data is analyzed with respect to a property to generate a result, and, based on the result, a selective performance of one of: a selection of a further control sequence, and termination of the actuation of the magnetic resonance device, is performed.

Abstract: A composition and method for reversing or preventing age-related metabolic and tissue degenerative changes in individuals. The method includes administering, orally, an effective amount of a first composition having methioninase enzyme. The method further includes administering, by a route other than the oral route, such as a parenteral route, an effective amount of a second composition having methioninase enzyme. The method further includes the steps of orally and/or parentally administering pyridoxal-L-phosphate.

Abstract: This disclosure provides a method of disinfecting a surface within an area, comprising the steps of: a) dispersing into the area a multiplicity of droplets of a first aqueous composition comprising a first iodine reactant compound that is either a peroxide compound or an iodine salt compound: b) allowing sufficient time for the first aqueous composition to distribute throughout the area, and to deposit and coalesce into a layer upon the surface: c) dispersing into the area a multiplicity of droplets of a second aqueous composition comprising a second iodine reactant compound that is the other of the first iodine reactant compound, and: d) again allowing sufficient time for the droplets of the second aqueous composition to deposit onto the coalesced layer of the first aqueous composition, thereby forming iodine and other iodine biocides in situ and disinfecting the surface.

Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Abstract: The present disclosure provides compositions of microparticles and uses thereof for removing toxic or undesirable molecules from an environment, e.g. the blood of a subject. The microparticles can be liposomes. In one embodiment, the aqueous phase of the liposomes contains (i) a system of generating NAD+ from NADH, and (ii) one or more enzymes that are involved in one or more NAD+-dependent reactions that remove the toxic or undesirable molecules from the environment. In one embodiment, the liposomes contain NADH oxidase, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) to remove ethanol from the blood of a subject.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: In various embodiments, the present invention provides pharmaceutical compositions and methods for treating cardiovascular-related disease.

Abstract: In various embodiments, the present invention provides pharmaceutical compositions and methods for treating cardiovascular-related disease.

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

Abstract: The present invention relates to enhancing mechanical properties of tissue such as collagenous or collagen-containing or elastin-containing tissue (e.g., tendons, ligaments, and cartilage) and treating related musculoskeletal and non-musculoskeletal conditions or injuries.

Abstract: Aseptic beverage products are prepared by mixing beverage ingredients together. The beverage ingredients include a protein source, such as a milk protein concentrate, and at least one buffering agent, with the at least one buffering agent including baking soda. Preferably, the at least one buffering agent further includes lemon juice concentrate. The pH of the beverage ingredients is adjusted to a level between 6.7 and 7.0 using the at least one buffering agent. The beverage ingredients are then heated to at least 139° C., and the at least one buffering agent prevents precipitation of the protein source during heating. Afterwards, the beverage ingredients are packaged as a plurality of aseptic beverage products.

Abstract: The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.

Abstract: An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.

Abstract: The invention proposes a new method for monitoring a health event in a mammal, comprising detecting at least one abnormal value within a series of values related to at least one biomarker, based on appropriate Z-scores.

Abstract: The present invention provides compositions and methods for reducing microbial contamination or infection in plants, animals, fabrics, and products therefrom. The present invention also provides compositions and methods for reducing human infections. In particular, it provides solid magnetic nanoparticles comprising bacteriostatic, bactericidal, fungistatic, or fungicidal enzymes in one component, and substrates for the enzymes in another component. The compositions are dormant and become active upon exposure to hydration and oxygen.

Abstract: The disclosure pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.

Abstract: A Transactivator of Transcription-frataxin (TAT-FXN) fusion polypeptide useful in treating subjects diagnosed with Friedreich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Abstract: Provided are methods for detecting or diagnosing a traumatic brain injury or TBI by detecting concentration levels miRNAs associated with TBI in saliva. Methods for controlled and normalized comparisons of salivary miRNA concentration levels are further provided. Assay kits comprising salivary miRNAs, probes and/or primers for detecting salivary miRNAs are also provided.

Abstract: Compositions comprising a combination of myeloperoxidase and a peroxide-producing oxidase and methods of using the compositions to inactivate gram negative bacterial lipopolysaccharides and lipid A endotoxin are provided.

Abstract: Provided herein are solid form water soluble curcuminoid compositions, including a curcuminoid; and a solubilization matrix, wherein the solubilization matrix is selected from one or more of the following: (i) chlorophyllin (CHL); (ii) green tea extract; (iii) epigallocatechin gallate (EGCG); (iv) Rutin; and (v) an aromatic amino acid. Alternatively, the solubilization matrix may include methylsulfonylmethane (MSM). Also provided herein are methods for producing curcuminoid compositions.

Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.

Abstract: The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.

Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.

Abstract: A transdermal peptide with a nuclear localization ability and having an amino acid sequence as shown in SEQ ID NO: 1 is disclosed. A fusion protein including a macromolecular protein with one end being linked to the transdermal peptide is also disclosed. The transdermal peptide can be used in the preparation of a medicament or a transdermal preparation for treating skin diseases. A medicament for treating a skin disease includes the transdermal peptide and a pharmaceutically acceptable excipient. The transdermal peptide enters the cells autonomously to locate in the nuclei, and can penetrate through the stratum corneum of the skin into cells in the dermis. The peptide is conveniently synthesized artificially and suitable for transdermal administration, and has a therapeutic potential via transdermal administration by carrying a drug for treating skin diseases.

Abstract: The invention provides compositions comprising milk thistle, dandelion root, and/or one or more antioxidant amino acids (e.g., n-acetyl L-cysteine) for the treatment and prevention of liver disease (hepatic insufficiency) in a mammal (e.g., equine). The composition may further comprise chitosan and/or additional components that prevent or treat liver disease or hepatic insufficiency (e.g., inulin, prebiotics).

Abstract: Disclosed is a composition and method for its use that includes Magnolia bark extract, Vitis vinifera extract, tocopherol or tocopherol acetate, and hydrogenated lecithin, lecithin, or dextrin.

Abstract: Compositions comprising vitamin E, vitamin C, and white tea extract for treating cutaneous signs of aging are disclosed. The compositions reduce signs of wrinkles and improve other skin conditions, such as increased skin elasticity and skin softness. Moreover, the prevention or treatment of unhealthy skin, such as aged skin or skin overexposed to sunlight, may advantageously be accomplished by the administration of the compositions of the present invention The compositions includes the combination of a number of different components, which interact to provide the desired improvements to the skin Further advantageous ingredients of the compositions may comprise, naturally occurring antioxidants extracted from e g grape seeds and tomato, an extract comprising glycosaminoglycans, a transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin, and a catechin-based component present in an amount sufficient to inhibit the presence of anti-collagen enzyme in the skin.

Abstract: The present invention provides compositions and methods for reducing bacterial contamination or infection in plants, animals, fabrics, and products therefrom. The present invention also provides compositions and methods for reducing human infections and the emergence of antibiotic resistance. In particular, the invention provides magnetic nanoparticles comprising bactericidal or bacteriostatic enzymes in one component, substrates for the enzymes in a second component, and a bactericidal chemical agent that works in combination or synergistically with the enzymes. The compositions are dormant and become active upon exposure to hydration, oxygen, or mixing.

Abstract: A method for improved anaerobic digestion is presented. The method includes mixing a volume of waste material with water to form a feedstock mixture. The volume of waste material includes an initial amount of biomass and the feedstock mixture includes methanogenic bacteria either naturally present in the waste material or introduced artificially. The method also includes introducing one or more promoter substances to the feedstock mixture. The one or more promoter substances are capable of modifying the methanogenic bacteria. Modifying includes stimulating novel enzyme production in the methanogenic bacteria.

Abstract: A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

Abstract: In some embodiments the present disclosure pertains to a method of activating an anti-tumor immune response for the treatment of a cancer. In some embodiments, such a method comprises detecting CD26 expression in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising adenosine deaminase. In some embodiments, the adenosine deaminase stimulates T cell proliferation and activates maturation of macrophages or dendritic cells. In some embodiments, the present disclosure pertains to a method for targeted reduction of adenosine or deoxyadenosine in a tumor microenvironment of a solid tumor.

Abstract: The present invention relates to the combination of an antiandrogen with a vitamin K antagonist or with a ?-glutamyl carboxylase inhibitor for use in the treatment or prevention of an androgen receptor positive cancer, such as prostate cancer, or a hyperactive androgen receptor signaling disease/disorder. The invention also relates to a vitamin K antagonist or a ?-glutamyl carboxylase inhibitor for use in resensitizing an antiandrogen-resistant prostate cancer to the treatment with an antiandrogen. The invention further provides a pharmaceutical composition comprising an antiandrogen, a vitamin K antagonist or a ?-glutamyl carboxylase inhibitor, and a pharmaceutically acceptable excipient.

Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Abstract: The disclosure concerns medical devices configured to utilize nitric oxide (NO) donor materials to release NO gas upon contact with moisture in order to mitigate bacterial proliferation, coagulation, or a combination thereof, at a site of a biosensor integrated within the medical device. A novel multi-lumen medical device is described, the device having a first lumen for containing the NO donor material and producing the NO gas, and having a second lumen for housing biosensor componentry. A channel between the first and second lumens serves to communicate NO gas from the first lumen to a sensor-volume of the biosensor.

Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.

Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.

Abstract: Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.

Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.

Abstract: Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and/or function.

Abstract: The invention relates to a composition for the detection of tooth demineralization. More specifically, the invention concerns a composition comprising a complex capable of producing an optical signal characteristic of the presence of free ions, the pharmaceutical uses of such a composition, and methods and a kit for the detection of active demineralization at tooth surfaces using such a composition.

Abstract: The present invention is directed to methods for improving assay specificity and performance in binding assays.

Abstract: Disclosed herein are compositions and methods for providing an antioxidant effect to a subject, e.g., modulating or otherwise improving oxidative stress pathways and/or neutralizing or reducing damaging reactive oxygen species (ROS).